Preferred Label : Cilgavimab/Tixagevimab;

NCIt synonyms : Monoclonal Antibody AZD7442; AZD8895 AZD1061; Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody AZD7442; AZD8895/AZD1061;

NCIt related terms : Monoclonal antibodies against SARS-CoV-2: tixagevimab/cilgavimab;

NCIt definition : A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab, that are isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

Drug name : Evusheld;

Molecule name : AZD 7442; AZD-7442;

NCI Metathesaurus CUI : CL1412606;

Details


Main resources

You can consult :


https://presse.inserm.fr/linserm-et-astrazeneca-sassocient-pour-tester-lefficacite-de-la-combinaison-danticorps-monoclonaux-azd7442-contre-la-covid-19-dans-le-cadre-de-lessai-europ/42799
2021
false
false
false
France
French
scientific and technical information
Cilgavimab/Tixagevimab
pneumonia, viral
coronavirus infections
pandemics
coronavirus infections
COVID-19

---
Nous contacter.
22/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.